GSK plc (GSK) Q4 Results Topped Forecasts as Specialty Medicines Jump 17%

GSK plc (NYSE:GSK) ranks among the best undervalued European stocks to bargain now. On February 4, GSK plc (NYSE:GSK) announced fourth-quarter net that outperformed expert estimates successful respective important metrics. Earnings per stock for the 4th came successful astatine $0.6989, 9.58% much than the forecast of $0.6378. Revenue besides surpassed forecasts, coming successful astatine $11.81 cardinal versus $11.36 billion, for a 3.96% upside surprise.

Pixabay/Public Domain

Specialty Medicines was a reasonably promising area, with 17% growth, portion Oncology outperformed expectations, with income up 43% from the aforesaid 4th past year.

GSK plc (NYSE:GSK) issued upbeat guidance for 2026, projecting 3-5% income growth. The institution forecasts halfway operating nett and net per stock to emergence adjacent faster, astatine 7-9%, implying further borderline expansion. The company’s absorption stated that oncology and respiratory medicines, arsenic good arsenic expanding pipeline assets, volition beryllium the main drivers of aboriginal growth.

GSK plc (NYSE:GSK) is simply a UK-based planetary biopharmaceutical institution that researches, develops, and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer, and immune-related disorders.

While we admit the imaginable of GSK arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.